ClinicalTrials.gg
CompletedNCT01956123ESTHER-2Updated Sep 6, 2023Results posted

Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

A Phase 3 interventional study of Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 13 sites in 11 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
513
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
3rd of 13
513 · median 220
Started
2014
with 1 other
Phase 3
6 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 2nd registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

This trial investigates the immunogenicity of FE 999049 in repeated cycles.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documents signed prior to screening evaluations related to this protocol
  • Participation in the pivotal efficacy trial (trial 000004/ESTHER-1)
  • Anti-FSH antibody results from baseline and at least one post-dosing assessment in the previous cycle(s) available.
  • Having undergone the oocyte retrieval procedure, or having had cycle cancellation prior to oocyte retrieval due to poor ovarian response or excessive ovarian response, in the previous cycle(s).
  • Failure to achieve ongoing pregnancy in the previous cycle(s).

Exclusion criteria

Exclusion Criteria:

  • Non-compliance to protocol compliance in the previous cycle(s).
  • Having undergone any stimulation with gonadotropins since the end-of-trial / end-of-cycle visit in the previous cycle
  • One or more follicles ≥10 mm observed on the transvaginal ultrasound prior to start of dosing on stimulation day 1
  • Severe OHSS in a previous cycle.
  • Any change to any of the eligibility criteria in the previous cycle(s).
  • Clinically relevant medical history since the previous cycle which precludes gonadotropin stimulation or is associated with a reduced chance of pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
513 participants (actual)

Study arms

  • Experimental
    A

    Follitropin Delta (FE 999049) (COS cycle 2)

    Drug: Follitropin Delta (FE 999049)

  • Active comparator
    B

    Follitropin Alfa (GONAL-F) (COS cycle 2)

    Drug: Follitropin Alfa (GONAL-F)

  • Experimental
    C

    Follitropin Delta (FE 999049) (COS cycle 3)

    Drug: Follitropin Delta (FE 999049)

  • Active comparator
    D

    Follitropin Alfa (GONAL-F) (COS cycle 3)

    Drug: Follitropin Alfa (GONAL-F)

06

What researchers measure

Primary outcomes

  1. Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles

    The proportion (percentage) of participants with at least one treatment-induced anti-FSH antibody response at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

    Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

Secondary outcomes

  1. Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles

    The proportion (percentage) of participants with treatment-induced anti-FSH antibodies with neutralising capacity at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

    Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

  2. Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity, After One and After Two Repeated Controlled Ovarian Stimulation Cycles

    The proportion (percentage) of participants with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated COS cycles is presented.

    Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

  3. Proportion (Percentage) of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS for Each Controlled Ovarian Stimulation Cycle

    The proportion (percentage) of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.

    Time frame: ≤9 days after triggering of final follicular maturation.

  4. Proportion (Percentage) of Subject With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response for Each Controlled Ovarian Stimulation Cycle

    Proportion (percentage) of participants with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  5. Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

    Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.

    Time frame: 5-6 weeks after blastocyst transfer

  6. Implantation Rate for Each Controlled Ovarian Stimulation Cycle

    Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.

    Time frame: 5-6 weeks after blastocyst transfer

  7. Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

    Ongoing pregnancy rate was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.

    Time frame: 10-11 weeks after blastocyst transfer

  8. Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle

    Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.

    Time frame: 10-11 weeks after blastocyst transfer

  9. Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle

    Participants self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessment performed is presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  10. Proportion (Percentage) of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) for Each Controlled Ovarian Stimulation Cycle

    Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.

    Time frame: >9 days after triggering of final follicular maturation

  11. Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle

    Incidences of confirmed technical malfunction of administration pen are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

07

Results

Posted Sep 21, 2018

Participant flow

A total of 32 investigational sites included participants to the trial : 3 in Belgium, 3 in Brazil, 3 in Canada, 3 in the Czech Republic, 2 in Denmark, 2 in Italy, 2 in Poland, 2 in Russia, 10 in Spain and 2 in United Kingdom.

COS Cycle 2
Participant flow — COS Cycle 2
MilestoneFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Started25226100
Completed23825400
Not completed14700
Withdrew: Protocol violation8300
Withdrew: Adverse event3400
Withdrew: Personal reasons2000
Withdrew: Withdrawal by subject1000
COS Cycle 3
Participant flow — COS Cycle 3
MilestoneFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Started009593
Completed008991
Not completed0062
Withdrew: Protocol violation0021
Withdrew: Adverse event0030
Withdrew: Personal reasons0010
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryProportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with at least one treatment-induced anti-FSH antibody response at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

Time frame:
Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)
Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles0.79 (0.10 to 2.84)0.38 (0.01 to 2.12)
SecondaryProportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with treatment-induced anti-FSH antibodies with neutralising capacity at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

Time frame:
Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)
Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles0.00 (0.00 to 1.45)0.00 (0.00 to 1.40)
SecondaryProportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity, After One and After Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated COS cycles is presented.

Time frame:
Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity, After One and After Two Repeated Controlled Ovarian Stimulation Cycles
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Treatment-induced anti-FSH antibodies0.79 (0.10 to 2.84)0.38 (0.01 to 2.12)1.05 (0.03 to 5.73)1.08 (0.03 to 5.85)
Antibodies with neutralising capacity0.00 (0.00 to 1.45)0.00 (0.00 to 1.40)0.00 (0.00 to 3.81)0.00 (0.00 to 3.89)
SecondaryProportion (Percentage) of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS for Each Controlled Ovarian Stimulation Cycle

The proportion (percentage) of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.

Time frame:
≤9 days after triggering of final follicular maturation.
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Early OHSS (any grade)0.82.31.10.0
Early OHSS (moderate/severe)0.01.90.00.0
Any preventive intervention1.61.90.01.1
Early OHSS (any grade) / preventive2.03.81.11.1
Early OHSS (moderate/severe) / preventive1.63.80.01.1
SecondaryProportion (Percentage) of Subject With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response for Each Controlled Ovarian Stimulation Cycle

Proportion (percentage) of participants with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subject With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Cycle cancelled due to poor ovarian response2.03.82.12.2
Cycle cancelled due to excessive ovarian response0.40.00.00.0
Triggering with GnRH agonist0.40.80.01.1
SecondaryVital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.

Time frame:
5-6 weeks after blastocyst transfer
Reported as:
Number · Percentage of participants
Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle29.4 (23.8 to 35.4)27.2 (21.9 to 33.0)27.4 (18.7 to 37.5)29.0 (20.1 to 39.4)
SecondaryImplantation Rate for Each Controlled Ovarian Stimulation Cycle

Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.

Time frame:
5-6 weeks after blastocyst transfer
Reported as:
Number · Percentage
Implantation Rate for Each Controlled Ovarian Stimulation Cycle
PercentageFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Implantation Rate for Each Controlled Ovarian Stimulation Cycle34.6 (28.8 to 40.8)30.6 (25.2 to 36.5)28.8 (21.2 to 37.3)32.2 (24.0 to 41.3)
SecondaryOngoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

Ongoing pregnancy rate was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.

Time frame:
10-11 weeks after blastocyst transfer
Reported as:
Number · Percentage of participants
Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle27.8 (22.3 to 33.7)25.7 (20.5 to 31.4)27.4 (18.7 to 37.5)28 (19.1 to 38.2)
SecondaryOngoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle

Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.

Time frame:
10-11 weeks after blastocyst transfer
Reported as:
Number · Percentage
Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle
PercentageFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle28.7 (23.3 to 34.7)25.5 (20.4 to 31.1)25.0 (17.9 to 33.3)28.9 (21.0 to 37.9)
SecondaryFrequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle

Participants self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessment performed is presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · Percentage of events
Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle
Percentage of eventsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle3.02.42.82.3
SecondaryProportion (Percentage) of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) for Each Controlled Ovarian Stimulation Cycle

Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.

Time frame:
>9 days after triggering of final follicular maturation
Reported as:
Number · Percentage of participants
Proportion (Percentage) of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Late OHSS (any grade)0.40.81.11.1
Late OHSS (moderate/severe)0.00.80.01.1
SecondaryTechnical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle

Incidences of confirmed technical malfunction of administration pen are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · Percentage of participants
Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle
Percentage of participantsFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle0.00.00.00.0

Adverse events

Collected over Adverse events (AEs) were recorded from signed informed consent to the end-of-cycle visit for COS cycle 2 (up to approximately 4.5 months) and again from screening to the end-of-cycle visit for COS cycle 3 (up to approximately 4.5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 (COS Cycle 2)0/252 (0%)4/252 (1.6%)70/252 (27.8%)
GONAL-F (COS Cycle 2)0/261 (0%)4/261 (1.5%)77/261 (29.5%)
FE 999049 (COS Cycle 3)0/95 (0%)0/95 (0%)26/95 (27.4%)
GONAL-F (COS Cycle 3)0/93 (0%)1/93 (1.1%)34/93 (36.6%)
Most frequent serious events
Most frequent serious events
EventFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
Ovarian hyperstimulation syndromeReproductive system and breast disorders0/2521/2610/951/93
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/2522/2610/950/93
Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions1/2521/2610/950/93
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2520/2610/950/93
Vomiting in pregnancyPregnancy, puerperium and perinatal conditions1/2520/2610/950/93
NephrolithiasisRenal and urinary disorders1/2520/2610/950/93
Most frequent other events
Most frequent other events
EventFE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)FE 999049 (COS Cycle 3)GONAL-F (COS Cycle 3)
HeadacheNervous system disorders19/25227/26111/9513/93
Biochemical pregnancyPregnancy, puerperium and perinatal conditions13/2528/2619/954/93
Procedural painInjury, poisoning and procedural complications13/25217/2615/958/93
Pelvic discomfortReproductive system and breast disorders6/25213/2610/956/93
Pelvic painReproductive system and breast disorders14/25211/2613/955/93
Abortion spontaneousPregnancy, puerperium and perinatal conditions10/2529/2615/954/93
Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions13/25210/2613/952/93

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)Total
COS cycle 2 — <=18 years000
COS cycle 2 — Between 18 and 65 years252261513
COS cycle 2 — >=65 years000
COS cycle 3 — <=18 years000
COS cycle 3 — Between 18 and 65 years9593188
COS cycle 3 — >=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 (COS Cycle 2)GONAL-F (COS Cycle 2)Total
COS cycle 2 — Female252261513
COS cycle 2 — Male000
COS cycle 3 — Female9593188
COS cycle 3 — Male000
08

Study locations

13 sites
  • UZ Brussel (there may be other sites in this country)
    Brussels, Belgium
  • Fertilitat and PUC-RS (there may be other sites in this country)
    Porto Alegre, Brazil
  • Pacific Centre for Reproductive Medicine
    Burnaby, British Columbia, Canada
  • Olive Fertility Centre
    Vancouver, British Columbia, Canada
  • Ottawa Fertility Centre
    Ottawa, Ontario, Canada
  • IVF CUBE SE (there may be other sites in this country)
    Prague, Czechia
  • Rigshospitalet Fertilitetsklinikken (there may be other sites in this country)
    Copenhagen, Denmark
  • Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre (there may be other sites in this country)
    Lille, France
  • Centro Natalità San Raffaele (there may be other sites in this country)
    Milano, Italy
  • The nOvum Clinic (there may be other sites in this country)
    Warszawa, Poland
  • IVF & Reproductive Genetics Center (there may be other sites in this country)
    Moscow, Russian Federation
  • IVI Sevilla (there may be other sites in this country)
    Sevilla, Spain
  • Glasgow Centre for Reproductive Medicine Ltd. (there may be other sites in this country)
    Glasgow, United Kingdom
09

References and documents

Publications

  • Havelock J, Aaris Henningsen AK, Mannaerts B, Arce JC; ESTHER-1 and ESTHER-2 Trial Groups. Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta. J Assist Reprod Genet. 2021 Oct;38(10):2651-2661. doi: 10.1007/s10815-021-02271-5. Epub 2021 Jul 13. PubMed 34254211 ↗
  • Fernandez-Sanchez M, Fatemi H, Garcia-Velasco JA, Heiser PW, Daftary GS, Mannaerts B. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach. Gynecol Endocrinol. 2023 Dec;39(1):2205952. doi: 10.1080/09513590.2023.2205952. PubMed 37156263 ↗
  • Nelson SM, Larsson P, Mannaerts BMJL, Nyboe Andersen A, Fauser BCJM. Anti-Mullerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta. Clin Endocrinol (Oxf). 2019 May;90(5):719-726. doi: 10.1111/cen.13956. Epub 2019 Mar 18. PubMed 30801744 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in May 2015, 14 months.

Results were first posted in Sep 2018, 3 years 4 months after primary completion. A results delay was requested in May 2016.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 14 months is below that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2013
First posted
Oct 8, 2013
StartActual
Mar 26, 2014
Primary completionActual
May 2015
CompletionActual
Jan 3, 2017
Results delay requested
May 2, 2016
Results first posted
Sep 21, 2018
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01956123
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Mar 26, 2014
Primary completion
May 2015
Completion
Jan 3, 2017
Results posted
Sep 21, 2018
Last update
Sep 6, 2023

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion